Superluminal Raises $60M Series B for Rare Obesity Treatments

1. 1U.S. biotech Superluminal Medicines raised $60 million in a Series B round to support research into rare genetic and hypothalamic obesity treatments.
2. 2The round was led by BVF Partners, with new participation from Deep Track Capital and Perceptive Advisors, while existing investors include Eli Lilly and NVIDIA.
3. 3The company aims to advance a selective, biased MC4R agonist lead candidate into Phase 1 by year-end and expand its GPCR-targeted pipeline.

Source Pharmaceutical Technology +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →